About: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 June 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2007 (uk) article scientifique publié en 2007 (fr) scientific article published on 11 June 2007 (en) 2007 թվականի հունիսի 11-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu en xunu de 2007 (ast)
publication date	wds:Q80466194-AB3DA69F-2608-4720-B2C2-065186EA087D
publication date	2007-06-11 00:00:00Z (xsd:dateTime)
author name string	wds:Q80466194-0DA03275-BD15-405B-AEB0-2E098EEDBE5E wds:Q80466194-494FB63F-64F0-4FEE-9E5B-034802B7CCB0 wds:Q80466194-4D9EABA7-E08F-4615-94CB-A266B02F18A8 wds:Q80466194-AD0AE282-365F-414D-BB58-F53D80E686B5 wds:Q80466194-AD71A370-094F-43D3-B464-7DF647236BE1 wds:Q80466194-C3294DEA-5489-4072-A7B1-B88EECD1B5CA
author name string	Manfred Kaufmann Günther Gademann Walter Jonat Holger Eidtmann Ivan Zuna Jörn Hilfrich
rdfs:label	Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (en) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (nl)
skos:prefLabel	Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (en) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (nl)
name	Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (en) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (nl)
author	wds:Q80466194-D500DAB9-FA7F-4225-89B6-25BFB8A918FE
author	Gunter von Minckwitz
title	wds:Q80466194-9C2367A7-55FA-4AAC-9739-6D762121E52F
title	Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study (en)
page(s)	wds:Q80466194-F1E2D7B3-9CC5-4B6A-B9AB-558151971C8F
page(s)	2664-2670
instance of	wds:Q80466194-3CB2D5CA-30C6-43C8-8547-39749D4ED9EE
instance of	scholarly article
main subject	wds:Q80466194-284AC8D2-7F29-4179-AD92-05632D5538A4 wds:Q80466194-9636110B-120C-42AD-9F09-15DB7695204C wds:Q80466194-E8AF9DEC-57A4-49F8-8BA6-8725A9C1CBC8
main subject	breast cancer anastrozole wd:Q412178
PubMed ID	wds:Q80466194-E126808A-E66D-4E2A-8E9C-5DDDE2D17D85
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17563395
PubMed ID	17563395
published in	wds:Q80466194-187D3140-27E5-4574-AE27-B300DEB6FA84
published in	Journal of Clinical Oncology
issue	wds:Q80466194-956C31B3-D005-4157-8268-1AB31C921035
volume	wds:Q80466194-EADD15D6-081E-4749-9064-D545F4FF35DD
issue	19
volume	25
DOI	wds:Q80466194-F961624E-5ED8-4C3E-B43F-11D6C0AD9FC2
DOI	http://dx.doi.org/10.1200/JCO.2006.08.8054
DOI	10.1200/JCO.2006.08.8054
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80466194
is cites work of	Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer Clinical utilities of aromatase inhibitors in breast cancer Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer Prevention and treatment of bone fragility in cancer patient Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors Aromatase, aromatase inhibitors, and breast cancer Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Status of adjuvant endocrine therapy for breast cancer Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials CYP2D6 and tamoxifen: DNA matters in breast cancer Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy Tamoxifen: the drug that came in from the cold Progress in endocrine approaches to the treatment and prevention of breast cancer The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials Aromatase inhibitors-induced bone loss in early breast cancer Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Update of the BIG 1-98 Trial: where do we stand? Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Update on the use of aromatase inhibitors in early-stage breast cancer Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update Exemestane in the adjuvant treatment of breast cancer in postmenopausal women

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software